Avalon GloboCare Corp

Avalon GloboCare Corp. is a holding company, which engages in the development of biotechnology and the provision of healthcare services. It operates through the following segments: Real Property Operating, Medical Related Consulting Services, and Development Services & Sales of Developed Products. It offers regenerative medicine, cell-based immunotherapy, exosome technology, and rehabilitation medicine through Avalon Cell and Avalon Rehab platforms. The company was founded on July 28, 2014 and is headquartered in Freehold, NJ.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Avalon GloboCare Corp. is a clinical-stage biotechnology company, which engages in the development of immune effector cell therapy and laboratory services. It operates through the Real Property Operating and Medical Related Consulting Services segments. The Real Property Operating segment includes property management fees, property insurance, real estate taxes, depreciation, repairs and maintenance fees, utilities and other expenses related to rental properties. The Medical Related Consulting segment relates to labor and related benefits, travel expenses, and related to consulting services. The company was founded on July 28, 2014 and is headquartered in Freehold, NJ.

FREEHOLD, N.J., Sept.  03, 2020  (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today announced the launch of its new allogeneic mesenchymal stromal cell (MSC) therapeutic platform. Avalon plans to develop the MSC platform as a potential therapy for COVID-19, the disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and for bone marrow transplant related complications of acute graft versus host disease (aGVHD).

Avalon GloboCare Announces Mesenchymal Stromal Cell Therapeutic Platform for COVID-19 and Acute Graft Versus Host Disease (aGVHD)

In anticipation of high demand, Avalon is working with Cellex to source manufacturing facilities and develop next generation COVID-19 testing kits In anticipation of high demand, Avalon is working with Cellex to source manufacturing facilities and develop next generation COVID-19 testing kits

Avalon GloboCare Announces Commercialization and Distribution Agreement with Cellex for COVID-19 Antibody Rapid Test Kit

FREEHOLD, N.J., Aug.  12, 2020  (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, announced today that Avalon has expanded and filed two provisional patents with the U.S. Patent and Trademark Office outlining compositions and methods of developing a decoy cytokine receptor-based filter system to treat “cytokine storms.”  These provisional patent applications are direct results of recent advancements related to Avalon’s  AVA-Trap™ therapeutic program. The technology utilizes cytokine receptor–Fc-fusion proteins to potentially serve as an antibody-like decoy to dampen the excessive cytokine release that occurs during hyper-activation of the immune system—a life-threatening condition called “cytokine storm” that can cause multi-organ failure and death. 

Avalon GloboCare Expands AVA-Trap™ Program to Treat COVID-19 and CAR-T Related Cytokine Storms

FREEHOLD, N.J., July  13, 2020  (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a clinical-stage global developer of cell-based technologies and therapeutics, today announced an update on its four scientific research and clinical development programs in cell therapy and COVID-19 related initiatives, including AVA-001 and AVA-011 (FLASH-CAR™), that leverage individualized CAR (Chimeric Antigen Receptor) T-cell therapy for immuno-oncology, as well as AVA-Trap™ for mitigating COVID-19 “cytokine storm,” and S-layer based COVID-19 vaccine development.

Avalon GloboCare Provides Updates on its Lead Scientific and Clinical Programs in CAR T-Cell Therapy and COVID-19

- Completed Phase I Clinical Study of 4-1BB Based Anti-CD19 CAR-T Therapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Avalon GloboCare Announces Successful Completion of Phase I Clinical Study of CAR T-Cell Therapy Candidate AVA-001

- Avalon forms strategic partnership with the University of Natural Resources and Life Sciences (BOKU) in Vienna, Austria and the nanotechnology laboratory of Professor Uwe B. Sleytr on a novel S-layer SARS-CoV-2 (COVID-19) vaccine

Avalon GloboCare Achieves Milestones in Advancing Novel Intranasal and Oral COVID-19 Vaccine Candidate

FREEHOLD, N.J., June  16, 2020  (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a clinical-stage global developer of cell-based technologies and therapeutics, announced today that the Company has appointed Professor Uwe B. Sleytr to its Scientific and Clinical Advisory Board.

Eminent Member of the Austrian Academy of Sciences, Professor Uwe B. Sleytr, Joins Avalon GloboCare's Scientific and Clinical Advisory Board

FREEDHOLD, N.J., June  08, 2020  (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a clinical-stage global developer of cell-based therapeutics and in vitro diagnostics, announced today that the Company has entered into a strategic partnership with GensKey Medical Technology Co. Ltd. to co-develop and commercialize point-of-care, rapid detection antibody tests to help identify whether a patient has been exposed to and has developed antibodies against SARS-CoV-2, the new coronavirus that causes COVID-19. The two companies will also co-develop and commercialize a polymerase chain reaction (PCR)-based diagnostic test to facilitate the diagnosis of an infection by the SARS-CoV-2 virus.  Both detection tests are already CE mark certified and are currently pending approval by the United States Food and Drug Administration (FDA) under the Emergency Use Authorization (EUA) pathway.  Avalon also intends to pursue the establishment of a cGMP facility in the United States for the manufacturing and assembly of the COVID-19 detection systems.

Avalon GloboCare Announces Diagnostic Platform for Point-of-Care Rapid Detection of COVID-19 (SARS-CoV-2) and Its Clinically Relevant Mutation Strains

FREEHOLD, N.J., May  08, 2020  (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a clinical-stage global developer of cell-based technologies and therapeutics, announced today that it has achieved significant milestones, advancing its next generation immune cell therapy using FLASH-CAR™ technology co-developed with the Company’s strategic partner Arbele Limited. The adaptable FLASH-CAR™ platform can be used to create personalized cell therapy from a patient’s own cells, as well as off-the-shelf cell therapy from a universal donor.

Avalon GloboCare Advances Next Generation Cellular Immunotherapy with FLASH-CAR™ Technology for Blood Cancers

FREEHOLD, N.J., April  28, 2020  (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a clinical-stage global developer of cell-based technologies and therapeutics, announced today that it has formed a strategic partnership with HydroPeptide, LLC, a leading epigenetics skin care company, to engage in co-development and commercialization of a series of clinical-grade, exosome-based  cosmeceutical and orthopedic products. 

Avalon GloboCare Partners with HydroPeptide, a Leader in Epigenetics Skin Care, to Accelerate Regenerative ACTEX™ Product Development and Commercialization

FREEHOLD, N.J., April  20, 2020  (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a clinical-stage global developer of cell-based technologies and therapeutics, announced today that it has achieved significant milestones advancing its AVA-Trap™ technology program towards combatting the cytokine storm associated with COVID-19 lung damage and mortality. 

Avalon GloboCare Achieves Major Milestones Advancing Immunotherapeutic Program towards Combatting Cytokine Storm Associated with COVID-19 Lung Damage and Mortality

FREEHOLD, N.J., Feb.  24, 2020  (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a clinical-stage global developer of cell-based technologies and therapeutics, announced today that it will present at the 32nd Annual ROTH Conference being held on March 15-17, 2020 at The Ritz-Carlton, Laguna Niguel in Dana Point, CA.

Avalon GloboCare to Present at the 32nd Annual ROTH Conference on March 16, 2020

FREEHOLD, N.J., Dec.  20, 2019  (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a clinical-stage global developer of cell-based technologies and therapeutics, today announced it has established a strategic partnership with China (Nanjing) Cell Valley (“CNCV”).  CNCV is currently one of the largest biotech zone initiatives in China with the goal of cultivating translational research and the technological advancement in the CellTech industry both in China and globally.  This partnership creates a platform to combine Avalon’s clinical expertise in cellular therapy, particularly in the Chimeric Receptor Antigen (CAR)-T area, with the infrastructural resources available within the CNCV.  Avalon will provide their expertise in multi-center clinical studies for cellular therapy while leveraging the immense network of affiliated hospitals and laboratories of the CNCV.  Additionally, Avalon will collaborate with CNCV to facilitate technical training, bio-production process standardization and harmonization. 

Avalon GloboCare Partners with China (Nanjing) Cell Valley to Advance Cellular Medicines

Avalon: Fortressing Capital Structure And Strengthening Fundamentals

Company to Remain with Zero Warrants Outstanding Company to Remain with Zero Warrants Outstanding

Avalon GloboCare Enters Agreement to Repurchase 100% of Outstanding Warrants

Avalon's CAR-Ts are ahead of their time due to key advantages over conventional medicines. AVA-101 shuttles enough genes to decimate two oncology targets (CD19 and CD22).

Avalon: Poised For Market Conquest

Unsecured credit facility carries 5% interest, all payments deferred for 36 months and is non-convertible into equity; Proceeds to be used to accelerate R&D, clinical studies and commercialization programs Unsecured credit facility carries 5% interest, all payments deferred for 36 months and is non-convertible into equity; Proceeds to be used to accelerate R&D, clinical studies and commercialization programs

Avalon GloboCare Announces $20 Million Credit Facility Provided by Company Chairman

General Electric

Avalon is gearing to hit a trifecta with three highly promising businesses, including exosome diagnostics, regenerative medicine, and cellular immunotherapy.

Avalon Forms A Colossal Partnership

Avalon GloboCare is an investment gem because it is brewing a highly diversified pipeline of potential blockbusters.

News for Avalon GloboCare Corp Stock (AVCO)